Kidney patients needed for Early-Stage drug safety study

NCT ID NCT07262333

Recruiting now Knowledge-focused Sponsor: Beijing Continent Pharmaceutical Co, Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This study tests a single dose of hydroxynidone capsules in 56 people with different levels of kidney function and healthy volunteers. The goal is to see how the drug moves through the body and if it is safe in people with kidney problems. Participants will have blood and urine tests to measure drug levels and will be monitored for side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL INSUFFICIENCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome kidney failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RENAL INSUFFICIENCY CHRONIC

Contacts and locations

Locations

Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
RECRUITING

Hubei, Wuhan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.